Introduction
Gaucher disease (GD)' is characterized by accumulation of glucosylceramide (glucocerebroside) in the lysosomes of macrophages. This is due to an inherited deficiency in the activity of glucocerebrosidase (GC), a lysosomal hydrolase ( 1 ) . Accumulation of lipid-laden macrophages results in hepatosplenomegaly, bone lesions, and, less commonly, in neurological ab- 1 . Abbreviations used in this paper: AP, acid phosphatase 5b; GC, glucocerebrosidase; GD, Gaucher disease; MU, methylumbelliferyl; SSI, severity scoring index.
normalities. For the most frequent nonneuronopathic phenotype (type 1 ) no strict correlation has been established between mutant genotypes, residual GC activity, and clinical expression ofthe disease ( 1, 2) . Even among siblings sharing the same GC genotype a striking difference in clinical symptoms may occur. It has been claimed that one of the most frequent mutant GC genotypes, homozygosity for the N370S mutation, is associated with mild disease (3, 4) . However, with this genotype, completely asymptomatic elderly individuals as well as severely affected young patients have been described. The limited correlation between genotype and phenotype suggests a more complicated pathophysiology of the disease and hampers genetic counselling. This has stimulated interest in secondary biochemical abnormalities associated with clinical manifestations of GD. Elevated plasma levels of acid phosphatase Sb (AP) are traditionally considered to be the most prominent secondary biochemical abnormality ( 1) . Moderate increases in plasma levels of f3-hexosaminidase, angiotensin converting enzyme, and lysozyme have also been described (1) . Recently enzyme supplementation therapy with alglucerase has become available. Since alglucerase is extremely costly and clinical improvement during enzyme supplementation therapy is slow (usually requiring at least 3-6 mo of treatment) (5, 6), the search for secondary biochemical abnormalities as possible early indicators of response to treatment has become an issue ofincreasing importance.
Here we report on an extreme elevation in chitotriosidase activity in the plasma of type 1 GD patients. The increased plasma levels of this novel enzyme were studied in relation to those of AP and lysozyme. Its possible source was investigated.
The clinical significance of these findings with respect to diagnosis, disease severity, and the monitoring of the efficacy of enzyme supplementation therapy is discussed.
Methods
All GD patients studied ( 16 males and 16 females; 3-72 yr old) were known to us either by contact with the Netherlands Gaucher Society or by referral to the Academic Medical Center. The diagnosis of GD was based on deficient glucocerebrosidase activity in leucocytes and/or urine samples (7, 8 Four patients were studied during therapy with intravenous alglucerase (Ceredase", Genzyme Corp., Cambridge, MA) at a dose of 4 U/kg, three times a week. Lysozyme activity towards cell wall suspension of Micrococcus lysodeikticus (Sigma Chemical Co.) was determined as described by Morsky (10).
Acid phosphatase activity was measured using 4-methylumbelliferyl phosphate as substrate in the presence of 3 M mercaptoethanol as described by Chambers et al. ( 
11).
Immunoprecipitation studies were performed with a rabbit antiserum to chitotriosidase (obtained after immunization ofa rabbit with the purified enzyme) or with anti-(lysozyme) antibodies (Zymed Labs., Inc., San Francisco, CA). Chitotriosidase was purified from the soluble fraction of a detergent-free homogenate of type 1 Gaucher spleen by a sequence of chromatographic steps, including chromatofocussing, gel filtration, and isoelectric focussing. Antibodies were coupled to protein A-Sepharose 4B beads, and an excess of the immobilized antibodies was incubated with plasma for 1 h at room temperature. After centrifugation, enzyme activities in the supernatants were measured as described above.
Monocytes were prepared as follows: mononuclear cells were isolated from citrated blood, diluted 1:1 with PBS, by Percoll density gradient centrifugation ( 1.077 g/cm3, 18 min, 2,000 rpm). After two washing steps, one in PBS supplemented with 0.38% sodium citrate and one in autologous plasma, cells were resuspended in Percoll ( 1.063 g/cm3) and carefully layered on Percoll ( 1.074 g/cm3). After centrifugation ( 18 min at 2,000 rpm), monocytes were collected from a band on top of the gradient. The cells were washed and resuspended in culture medium (RPMI 1640 supplemented with L-glutamine and 10% human AB serum). The monocyte preparations had a purity exceeding 85% as judged by Giemsa staining. Monocytes were cultured in plastic petri dishes at a concentration of 4 X 105 cells/ml in 10 ml of culture medium. During 20 d ofculture, 1.8 ml ofthe culture supernatant was collected daily and replaced by fresh medium. After centrifugation, the supernatant was immediately frozen at -20°C.
Results
Fig. 1 shows the plasma levels ofchitotriosidase, lysozyme, and AP in 32 untreated symptomatic GD patients (III), 3 asymptomatic GC-deficient individuals (II), and 50 healthy controls (I). Chitotriosidase activity was strikingly increased in 30 GD patients (median, 12,824; range, 3,122-65,349 nmol/ml per h) as compared with asymptomatic GC-deficient individuals (90, 166, and 195 nmol/ml per h) and healthy controls (median, 20; range, 4-76 nmol/ml per h) (Fig. 1 A) . In the 30 GD patients chitotriosidase was increased 2 100-fold, the median value being > 600 times the median value of the control subjects. However, in two GD patients, chitotriosidase activity was almost absent (2 and 3 nmol/ml per h). Mixing experiments indicated that the plasma samples of these patients contained no inhibitors ofthe enzyme. In the three asymptomatic GC-deficient individuals the elevation with respect to the median control value was only 9.7, 4.5, and 8.3 times.
Since it is known that the 4 MU-chitotrioside substrate can also be hydrolyzed by lysozyme ( 12) (Fig. 1, A and B) .
In GD patients, the macrophages are a likely cellular source of biochemical abnormalities ( 1) . We therefore studied the production and secretion of chitotriosidase activity during differentiation of cultured monocytes into macrophages. During the first 5 d of culture of purified monocytes, chitotriosidase activity was found to be absent both in the cells and supernatant. After morphological differentiation of monocytes into macrophages, the cells began to produce and secrete increasing amounts of chitotriosidase (Fig. 2) . AP was also produced and secreted after 5 d of culture (Fig. 2) ( 14) . Fig. 3 , A-D, shows that chitotriosidase levels rapidly declined during enzyme supplementation therapy, starting already within 1-2 mo. 
Discussion
Chitotriosidase activity in plasma samples of untreated type 1 GD patients was found to be strikingly elevated. Moreover, chitotriosidase activity began to decline rapidly after the initiation ofenzyme supplementation therapy. Previously, the occurrence of a chitotetraosidase activity in normal human plasma has been reported ( 15 ). The chitotriosidase described here resembles the plasma chitotetraosidase with respect to the apparent basic isoelectric point and nonbinding to the lectin concanavalin A. It is therefore possible that chitotriosidase and chitotetraosidase activities are due to a single enzyme. An increase in either chitotriosidase or chitotetraosidase activities in association with pathological conditions has so far not been reported. The increase in plasma chitotriosidase in GD patients is far more pronounced than the increase in AP activity, which has often been used as an important diagnostic hallmark of the disease ( 16, 17) . Even in asymptomatic GC-deficient individuals a slight elevation in chitotriosidase activity was found, whereas in these individuals AP levels were well within the control range. Because of the simplicity and sensitivity of the assay, determination of chitotriosidase activity can conveniently be used for biochemical confirmation of the diagnosis of GD, in addition to the demonstration of glucocerebrosidase deficiency. Surprisingly, in two of the 32 GD patients studied we repeatedly found an almost complete absence ofchitotriosidase activity. In these cases residual enzyme activity was found to be due to lysozyme, which also has catalytic activity towards 1290 Hollak et al. towards the same substrate suggests that chitotriosidase may also have a function in host defense mechanisms, e.g., through cleavage of bacterial cell wall polysaccharide. Another important question relates to the source of chitotriosidase. GD is characterized by the presence of large numbers ofmacrophages loaded with glucosylceramide. It therefore seemed likely that these so-called "Gaucher cells" are the main source of the plasma chitotriosidase activity. Our in vitro data support the hypothesis that the enzyme is macrophage derived. However, the rapid decline in chitotriosidase levels after the start of enzyme supplementation therapy, preceding objective clinical improvement, suggests that the production of chitotriosidase is not a simple function ofthe number of lipid-laden macrophages. This is also suggested by the poor correlation between chitotriosidase levels and SSI, which mainly focusses on the extent oforgan involvement in GD. It is more likely that in GD a particular state of activation or differentiation of macrophages or of their precursors leads to the excessive production of chitotriosidase. The rapid decrease in chitotriosidase activity during supplementation with GC may (initially) reflect an alteration in this state rather than a decrease in Gaucher cell mass. The changes in chitotriosidase levels upon enzyme supplementation therapy suggest that the enzyme can be a promising parameter for assessing the clinical response to treatment. More extended studies are needed to relate clinical improvement to decrease in chitotriosidase levels.
Since activated macrophages contribute to the pathophysiology of many diseases, chitotriosidase activity was determined in plasma samples ofa number ofpatients with granulomatous immunological disorders (Wegener's granulomatosis, sarcoidosis) or granulomatous infectious diseases (tuberculosis, leishmaniasis, and leprosy). Elevated enzyme levels were only found for some patients with leishmaniasis and sarcoidosis (Hollak, C. E. M., and J. M. F. G. Aerts, manuscript in preparation). However, in these cases even the highest chitotriosidase levels did not exceed 1,800 nmol/ml per h, being clearly less than the lowest chitotriosidase activities found for symptomatic GD patients. In plasma samples of patients with acute and chronic myeloid leukemia (diseases that are commonly listed in the differential diagnosis of GD) chitotriosidase activities were within or slightly above the normal range.
It is of importance to note that chitotriosidase levels were found to be only moderately increased in the asymptomatic patients studied and > 100-fold in the mildly affected patients. This difference is unique with respect to secondary markers and suggests that increasing chitotriosidase levels can prove to be a sensitive harbinger ofclinical symptoms and consequently may contribute to considerations concerning early therapeutic intervention.
